Mortality in Sepsis

  • I. Matot
  • C. L. Sprung
Conference paper


In the United States, 500,000 patients develop sepsis each year, less than half of whom have associated positive blood cultures. It is estimated that about half of the 250,000 cases of sepsis with bacteremia show evidence of organ dysfunction [1, 2]. Septic shock is the most frequent cause of death in intensive care units in the United States [3]. Mortality rates due to sepsis and septic shock are currently estimated to be 20–70% [2–4]. Despite major advances in antimicrobial therapy, critical care, and surgical techniques, there has been little improvement in morbidity and mortality due to sepsis or septic shock during the past 30 years. The difficulty in improving the outcome in patients with sepsis may be less a reflection of the potency of new therapies than simply an indication of the complex pathophysiologic process and the severity of underlying disease. It may also be related to a sicker population that becomes septic.


Septic Shock Severe Sepsis Positive Blood Culture Blood Lactate Level Sepsis Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bone RC, Fisher CJ, Clemmer TP et al (1989) Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Group. Crit Care Med 17:389–393PubMedCrossRefGoogle Scholar
  2. 2.
    Ziegler EJ, Fisher CJ, Sprung CL et al (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med 324:429–436PubMedCrossRefGoogle Scholar
  3. 3.
    Parrillo JE, Parker MM, Natanson C (1990) Septic shock in humans. Ann Intern Med 113: 227–242PubMedCrossRefGoogle Scholar
  4. 4.
    Bone RC, Fisher CJ, Clemmer TP et al (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317: 653–658PubMedCrossRefGoogle Scholar
  5. 5.
    Knaus WA, Harrell FE, LaBrecque JF et al (1996) Use of predicted risk mortality to evaluate the effiicacy of anticytokine therapy in sepsis. Crit Care Med 24:46–54PubMedCrossRefGoogle Scholar
  6. 6.
    Knaus WA, Harrell FE, Fisher CJ et al (1993) The clinical evaluation of new drugs for sepsis. JAMA 270:1233–1241PubMedCrossRefGoogle Scholar
  7. 7.
    Arreguri LM, Moyes DG, Lipman J (1991) Comparison of disease severity scoring systems in septic shock. Crit Care Med 19:1165–1171CrossRefGoogle Scholar
  8. 8.
    Chelluri L, Pinsky MR, Donahoe MP et al (1993) Long-term outcome of critically ill eldery patients requiring intensive care. JAMA 269:3119–3123PubMedCrossRefGoogle Scholar
  9. 9.
    Sasse KC, Nauenberg E, Long A et al (1995) Long-term survival after intensive care unit admission with sepsis. Crit Care Med 23:1040–1047PubMedCrossRefGoogle Scholar
  10. 10.
    Buisson CB, Doyon F, Carlet J et al (1995) Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. JAMA 274:968–974CrossRefGoogle Scholar
  11. 11.
    Bone RC (1991) The pathogenesis of sepsis. Ann Intern Med 115:457–469PubMedCrossRefGoogle Scholar
  12. 12.
    Parrillo JE (1993) Pathogenic mechanisms of septic shock. N Engl J Med 328:1471–1477PubMedCrossRefGoogle Scholar
  13. 13.
    Michie HR, Manogue KR, Spriggs DR (1988) Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481–1486PubMedCrossRefGoogle Scholar
  14. 14.
    Cannon JG, Tompkins RG, Gelfand JA (1990) Circulating IL-1 and TNF in septic shock and experimental endotoxin fever. J Infect Dis 161:79–84PubMedCrossRefGoogle Scholar
  15. 15.
    Barriere SL, Lowry SF (1995) An overview of mortality risk prediction in sepsis. Crit Care Med 23:376–393PubMedCrossRefGoogle Scholar
  16. 16.
    Abraham E, Wunderink R, Silverman H et al (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA 273:934–941PubMedCrossRefGoogle Scholar
  17. 17.
    Fisher CJ, Dhainaut JFA, Opal SM et al (1994) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 271:1836–1843PubMedCrossRefGoogle Scholar
  18. 18.
    Tuchschmidt J, Fried J, Swinney R et al (1989) Early hemodynamic correlates of survival in patients with septic shock. Crit Care Med 17:719–723PubMedCrossRefGoogle Scholar
  19. 19.
    Rackow EC, Astiz ME, Weil MH (1988) Cellular oxygen metabolism during sepsis and shock: the relationship of oxygen consumption to oxygen delivery. JAMA 259:1989–1993PubMedCrossRefGoogle Scholar
  20. 20.
    Bland RD, Shoemaker WC, Abraham E et al (1985) Hemodynamic and oxygen transport patterns in surviving and nonsurviving postoperative patients. Crit Care Med 13:85–90PubMedCrossRefGoogle Scholar
  21. 21.
    Shoemaker WC, Appel PL, Waxman K et al (1982) Clinical trial of survivors’ cardiorespiratory patterns as therapeutic goals in critically ill postoperative patients. Crit Care Med 10:398–403PubMedCrossRefGoogle Scholar
  22. 22.
    Edward J, Brown G, Nightengale P et al (1989) Use of survivors cardiorespiratory values as therapeutic goals in septic shock. Crit Care Med 17:1098–1103CrossRefGoogle Scholar
  23. 23.
    Tuchschmidt J, Fried J, Astiz M et al (1992) Elevation of cardiac output and oxygen delivery improves outcome in septic shock. Chest 102:216–220PubMedCrossRefGoogle Scholar
  24. 24.
    Gattinoni L, Brazzi L, Pelosi P et al (1995) A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med 333:1025–1032PubMedCrossRefGoogle Scholar
  25. 25.
    Bakker J, Coffernils M, Leon M et al (1991) Blood lactate levels are superior to oxygenderived variables in predicting outcome in human septic shock. Chest 4:956–962CrossRefGoogle Scholar
  26. 26.
    Metrangolo L, Fiorillo M, Friedman G et al (1995) Early hemodynamic course of septic shock. Crit Care Med 23:1971–1975PubMedCrossRefGoogle Scholar
  27. 27.
    Friedman G, Berlot G, Kahn RJ (1995) Combined measurements of blood lactate levels and gastric intramucosal pH in patients with severe sepsis. Crit Care Med 23:1184–1193PubMedCrossRefGoogle Scholar
  28. 28.
    Baue AE (1975) Multiple, progressive, or sequential systems failure: A syndrome of the 1970’s. Arch Surg 110:779–781PubMedCrossRefGoogle Scholar
  29. 29.
    Deitch EA (1992) Multiple organ failure: pathophysiology and potential future therapy. Ann Surg 216:117–134PubMedCrossRefGoogle Scholar
  30. 30.
    American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (1992) Definitions for sepsis and multiple organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874CrossRefGoogle Scholar
  31. 31.
    Pittet D, Thievent B, Wenzel RP et al (1996) Bedside prediction of mortality from bacteremic sepsis. A dynamic analysis of ICU patients. Am J Respir Crit Care Med 153:684–693PubMedCrossRefGoogle Scholar
  32. 32.
    Marshall JC, Cook DJ, Christou NV et al (1995) Multiple organ dysfunction score: a reliable descriptor of complex clinical outcome. Crit Care Med 23:1638–1652PubMedCrossRefGoogle Scholar
  33. 33.
    Knaus WA, Draper EA, Wagner DP (1985) Prognosis in acute organ system failure. Ann Surg 202:685–692PubMedCrossRefGoogle Scholar
  34. 34.
    Goris RJA, te Boekhurts TPA, Nuytink JKS (1985) Multiple-organ failure: generalized autodestructive inflammation? Arch Surg 120:1109–1115PubMedCrossRefGoogle Scholar
  35. 35.
    Knaus WA, Harrell FE, Fisher CJ (1993) The clinical evaluation of new drugs for sepsis: a prospective study design based on survival analysis. JAMA 270:1233–1241PubMedCrossRefGoogle Scholar
  36. 36.
    Kreger BE, Kraven DE, McCabe WR (1980) Gram-negative bacteremia. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 68:344–355PubMedCrossRefGoogle Scholar
  37. 37.
    Sprung CL, Peduzzi PL, Shatney CH et al (1990) Impact of encephalopathy on mortality in sepsis syndrome. Crit Care Med 18:801–806PubMedCrossRefGoogle Scholar
  38. 38.
    Eidelman LA, Putterman D, Putterman C et al (1996) The spectrum of septic encephalopathy. JAMA 275:470–473PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 1997

Authors and Affiliations

  • I. Matot
  • C. L. Sprung

There are no affiliations available

Personalised recommendations